Argenx presents new efgartigimod data at eular 2025 highlighting positive phase 2 proof-of-concept results in myositis and sjogren's disease

Alkivia data demonstrate significant improvement in muscle strength and physical function in myositis patients treated with efgartigimod rho data show efgartigimod achieved sustained reduction in autoantibodies and improved functional outcomes in patients with sjogren's disease; program granted u.s. fda fast track designation argenx committed to new therapeutic areas in rheumatology with ongoing phase 3 studies in myositis (alkivia) and sjogren's disease (unity) june 11, 2025, 12:01 am cet amsterdam, the netherlands – argenx se (euronext & nasdaq: argx), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the presentation of positive results from phase 2 studies evaluating vyvgart® (iv: efgartigimod alfa-fcab and sc or hytrulo: efgartigimod alfa and hyaluronidase-qvfc) in sjogren's disease (sjd) and idiopathic inflammatory myopathies (iim or myositis) at the european congress of rheumatology, eular 2025, from june 11 – 14 in barcelona, spain. argenx also announced that the u.s. food and drug administration (fda) has granted efgartigimod fast track designation (ftd) for the treatment of primary sjogren's disease.
ARGX Ratings Summary
ARGX Quant Ranking